Suppr超能文献

急性髓系白血病骨髓中的纤溶酶原激活剂:与正常骨髓中的组织型纤溶酶原激活剂(t-PA)不同,尿激酶型纤溶酶原激活剂(u-PA)存在。

Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.

作者信息

McWilliam N, Robbie L, Booth N, Bennett B

机构信息

Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill.

出版信息

Br J Haematol. 1998 Jun;101(4):626-31. doi: 10.1046/j.1365-2141.1998.00762.x.

Abstract

Leukaemic and normal bone marrow samples were compared in terms of their content of the fibrinolytic agents, tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) and their inhibitors. plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2). Normal marrow contained t-PA as the principal plasminogen activator, whereas in leukaemic marrow samples u-PA was the predominant activator. Both normal and leukaemic marrows contained PAI-1 in similar amounts, but whereas normal marrow contained significant amounts of PAI-2 the leukaemic marrows contained very little. Plasminogen activators were present in uncomplexed, active forms and plasmin-alpha2-antiplasmin complexes were generated locally more prominently in leukaemic marrows. u-PA associated with blast cells may contribute to the severe forms of haemorrhage sometimes occurring in myeloid types of leukaemia.

摘要

对白血病骨髓样本和正常骨髓样本的纤溶因子、组织型纤溶酶原激活物(t-PA)、尿激酶型纤溶酶原激活物(u-PA)及其抑制剂纤溶酶原激活物抑制剂1和2(PAI-1和PAI-2)的含量进行了比较。正常骨髓以t-PA作为主要的纤溶酶原激活物,而在白血病骨髓样本中,u-PA是主要的激活物。正常骨髓和白血病骨髓中PAI-1的含量相似,但正常骨髓含有大量的PAI-2,而白血病骨髓中含量极少。纤溶酶原激活物以未结合的活性形式存在,并且纤溶酶-α2-抗纤溶酶复合物在白血病骨髓中更显著地局部生成。与原始细胞相关的u-PA可能导致髓系白血病有时出现的严重出血形式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验